

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA: Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
No.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?
N/A.

3. Has any change to the draft scope been agreed to highlight potential equality issues?
No changes to the draft scope have been made.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No additional stakeholders have been identified.

**Approved by Associate Director (name):** Alex Filby (Technical Adviser)

**Date:** 27/07/20